425 related articles for article (PubMed ID: 31801598)
21. Suppression of tumor immune microenvironment via microRNA-1 after epidermal growth factor receptor-tyrosine kinase inhibitor resistance acquirement in lung adenocarcinoma.
Kawana S; Saito R; Miki Y; Kimura Y; Abe J; Sato I; Endo M; Sugawara S; Sasano H
Cancer Med; 2021 Jan; 10(2):718-727. PubMed ID: 33305905
[TBL] [Abstract][Full Text] [Related]
22. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.
Donev IS; Wang W; Yamada T; Li Q; Takeuchi S; Matsumoto K; Yamori T; Nishioka Y; Sone S; Yano S
Clin Cancer Res; 2011 Apr; 17(8):2260-9. PubMed ID: 21220474
[TBL] [Abstract][Full Text] [Related]
23. Combination therapy with anti-ErbB3 monoclonal antibodies and EGFR TKIs potently inhibits non-small cell lung cancer.
Noto A; De Vitis C; Roscilli G; Fattore L; Malpicci D; Marra E; Luberto L; D'Andrilli A; Coluccia P; Giovagnoli MR; Normanno N; Ruco L; Aurisicchio L; Mancini R; Ciliberto G
Oncotarget; 2013 Aug; 4(8):1253-65. PubMed ID: 23896512
[TBL] [Abstract][Full Text] [Related]
24. The Significance of MMP-1 in EGFR-TKI-Resistant Lung Adenocarcinoma: Potential for Therapeutic Targeting.
Saito R; Miki Y; Ishida N; Inoue C; Kobayashi M; Hata S; Yamada-Okabe H; Okada Y; Sasano H
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29463039
[TBL] [Abstract][Full Text] [Related]
25. Enhanced YAP expression leads to EGFR TKI resistance in lung adenocarcinomas.
Lee TF; Tseng YC; Nguyen PA; Li YC; Ho CC; Wu CW
Sci Rep; 2018 Jan; 8(1):271. PubMed ID: 29321482
[TBL] [Abstract][Full Text] [Related]
26. Diarylheptanoid 35d overcomes EGFR TKI resistance by inducing hsp70-mediated lysosomal degradation of EGFR in EGFR-mutant lung adenocarcinoma.
Hong X; Hsieh MT; Tseng TY; Lin HY; Chang HC; Yau ST; Cheng WC; Ke B; Liao HH; Wu CY; Liu AA; Wu MM; Huang KY; Yang PC; Kuo SC; Hung MC; Lee PC
J Biol Chem; 2023 Jun; 299(6):104814. PubMed ID: 37178919
[TBL] [Abstract][Full Text] [Related]
27. Podoplanin-positive cancer-associated fibroblasts in the tumor microenvironment induce primary resistance to EGFR-TKIs in lung adenocarcinoma with EGFR mutation.
Yoshida T; Ishii G; Goto K; Neri S; Hashimoto H; Yoh K; Niho S; Umemura S; Matsumoto S; Ohmatsu H; Iida S; Niimi A; Nagai K; Ohe Y; Ochiai A
Clin Cancer Res; 2015 Feb; 21(3):642-51. PubMed ID: 25388165
[TBL] [Abstract][Full Text] [Related]
28. PAK1 Is a Novel Therapeutic Target in Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma Activated by the PI3K/AKT Signaling Regardless of EGFR Mutation.
Wu DW; Wu TC; Chen CY; Lee H
Clin Cancer Res; 2016 Nov; 22(21):5370-5382. PubMed ID: 27178741
[TBL] [Abstract][Full Text] [Related]
29. Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal.
Li L; Han R; Xiao H; Lin C; Wang Y; Liu H; Li K; Chen H; Sun F; Yang Z; Jiang J; He Y
Clin Cancer Res; 2014 May; 20(10):2714-26. PubMed ID: 24644001
[TBL] [Abstract][Full Text] [Related]
30. Cigarette smoke induces aberrant EGF receptor activation that mediates lung cancer development and resistance to tyrosine kinase inhibitors.
Filosto S; Becker CR; Goldkorn T
Mol Cancer Ther; 2012 Apr; 11(4):795-804. PubMed ID: 22302097
[TBL] [Abstract][Full Text] [Related]
31. Acquisition of cancer stem cell-like properties in non-small cell lung cancer with acquired resistance to afatinib.
Hashida S; Yamamoto H; Shien K; Miyoshi Y; Ohtsuka T; Suzawa K; Watanabe M; Maki Y; Soh J; Asano H; Tsukuda K; Miyoshi S; Toyooka S
Cancer Sci; 2015 Oct; 106(10):1377-84. PubMed ID: 26202045
[TBL] [Abstract][Full Text] [Related]
32. DDX3X induces primary EGFR-TKI resistance based on intratumor heterogeneity in lung cancer cells harboring EGFR-activating mutations.
Nozaki K; Kagamu H; Shoji S; Igarashi N; Ohtsubo A; Okajima M; Miura S; Watanabe S; Yoshizawa H; Narita I
PLoS One; 2014; 9(10):e111019. PubMed ID: 25343452
[TBL] [Abstract][Full Text] [Related]
33. An activation of LC3A-mediated autophagy contributes to de novo and acquired resistance to EGFR tyrosine kinase inhibitors in lung adenocarcinoma.
Nihira K; Miki Y; Iida S; Narumi S; Ono K; Iwabuchi E; Ise K; Mori K; Saito M; Ebina M; Sato I; Maemondo M; Yamada-Okabe H; Kondo T; Sasano H
J Pathol; 2014 Oct; 234(2):277-88. PubMed ID: 24687913
[TBL] [Abstract][Full Text] [Related]
34. The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer.
Zhang Y; Zeng Y; Liu T; Du W; Zhu J; Liu Z; Huang JA
Respir Res; 2019 Jul; 20(1):164. PubMed ID: 31331328
[TBL] [Abstract][Full Text] [Related]
35. Dioscin overcome TKI resistance in EGFR-mutated lung adenocarcinoma cells via down-regulation of tyrosine phosphatase SHP2 expression.
Wang YC; Wu DW; Wu TC; Wang L; Chen CY; Lee H
Int J Biol Sci; 2018; 14(1):47-56. PubMed ID: 29483824
[TBL] [Abstract][Full Text] [Related]
36. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.
Sette G; Salvati V; Mottolese M; Visca P; Gallo E; Fecchi K; Pilozzi E; Duranti E; Policicchio E; Tartaglia M; Milella M; De Maria R; Eramo A
Cell Death Dis; 2015 Aug; 6(8):e1850. PubMed ID: 26247735
[TBL] [Abstract][Full Text] [Related]
37. Synergistic effects of gefitinib and thalidomide treatment on EGFR-TKI-sensitive and -resistant NSCLC.
Xia X; Liu Y; Liao Y; Guo Z; Huang C; Zhang F; Jiang L; Wang X; Liu J; Huang H
Eur J Pharmacol; 2019 Aug; 856():172409. PubMed ID: 31132355
[TBL] [Abstract][Full Text] [Related]
38. A real-world study and network pharmacology analysis of EGFR-TKIs combined with ZLJT to delay drug resistance in advanced lung adenocarcinoma.
Han X; Liang L; He C; Ren Q; Su J; Cao L; Zheng J
BMC Complement Med Ther; 2023 Nov; 23(1):422. PubMed ID: 37990309
[TBL] [Abstract][Full Text] [Related]
39. Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung Adenocarcinoma.
Stewart EL; Mascaux C; Pham NA; Sakashita S; Sykes J; Kim L; Yanagawa N; Allo G; Ishizawa K; Wang D; Zhu CQ; Li M; Ng C; Liu N; Pintilie M; Martin P; John T; Jurisica I; Leighl NB; Neel BG; Waddell TK; Shepherd FA; Liu G; Tsao MS
J Clin Oncol; 2015 Aug; 33(22):2472-80. PubMed ID: 26124487
[TBL] [Abstract][Full Text] [Related]
40. USP22 promotes resistance to EGFR-TKIs by preventing ubiquitination-mediated EGFR degradation in EGFR-mutant lung adenocarcinoma.
Zhang H; Han B; Lu H; Zhao Y; Chen X; Meng Q; Cao M; Cai L; Hu J
Cancer Lett; 2018 Oct; 433():186-198. PubMed ID: 29981430
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]